Contact number:
400 007 5658
-
R&D
Anbison focuses on the research, development, and manufacturing of sustained-release and controlled release drug formulations. We continuously develop cutting -edge dosage forms and hard-to-copy drugs and actively strenthen our pipeline in improved new drugs and complex drugs.
To learn more, please slide the window left and right
| Product Name | Status | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Compound Sodium Valproate and Valproic Acid Sustained Release Tablets | Submitted to NMPA | ||||
| Exemestane Tablets | Submitted to NMPA | ||||
| Flurbiprofen Cataplasms | Submitted to NMPA | ||||
| Cyclosporin Eye Drops/cyclosporine ophthalmic emulsion（0.05%） | Submitted to FDA | ||||
| Perindopril arginine and amlodipine besylate tablets | Submitted to NMPA | ||||
| Eperisone Hydrochloride Tablets | Submitted to NMPA | ||||
| Metformin Hydrochloride and Glipizide Tablets | Submitted to NMPA | ||||
| Nalmefene Hydrochloride Injection | Submitted to NMPA | ||||
| Tacrolimus Sustained-release Capsules | Submitted to NMPA | ||||
| Toremifene Citrate Tablets | Submitted to NMPA | ||||
| Dapagliflozin and Metformin Hydrochloride Extended-release Tablets | Submitted to NMPA | ||||
| Vitamin K1 Injection | Submitted to NMPA | ||||
| Mesalamine Extended Release Capsules | Submitted to FDA |